Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Research advances in osteoarthritis management

Published byAlbert Lindberg Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1 Research advances in osteoarthritis management"— Presentation transcript:

1 Figure 1 Research advances in osteoarthritis management
Figure 1 | Research advances in osteoarthritis management. A novel drug-delivery system can prolong the analgesic effect of intra-articular glucocorticoids for knee osteoarthritis (OA). Results of clinical trials shed light on the long-term effects of intra-articular glucocorticoids and on the therapeutic potential of a small-molecule inhibitor of the Wnt signalling pathway for OA. Fz, Frizzled; LRP, lipoprotein receptor-related protein. McAlindon, T. E. & Bannuru, R. R. (2018) Latest advances in the management of knee OA Nat. Rev. Rheumatol. doi: /nrrheum

Download ppt "Figure 1 Research advances in osteoarthritis management"

Similar presentations

EULAR OA Trial Bank Study Group Predicting treatment response in subgroups of osteoarthritis patients using individual patient data of worldwide available.

EULAR OA Trial Bank Study Group Predicting treatment response in subgroups of osteoarthritis patients using individual patient data of worldwide available.
The Effect of Intra-Articular Steroids on Cartilage in Knee Osteoarthritis.

The Effect of Intra-Articular Steroids on Cartilage in Knee Osteoarthritis.
of different experimental arthritis models

of different experimental arthritis models
Figure 3 Metabolism in homeostatic chondrocytes

Figure 3 Metabolism in homeostatic chondrocytes
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 1 Factors underlying metabolic alterations in osteoarthritis

Figure 1 Factors underlying metabolic alterations in osteoarthritis
Figure 4 The mechanistic link between the epithelial-to-mesenchymal

Figure 4 The mechanistic link between the epithelial-to-mesenchymal
Figure 1 Structure of TNF antagonists

Figure 1 Structure of TNF antagonists
Figure 1 Induction of immune tolerance

Figure 1 Induction of immune tolerance
Figure 3 Methods to detect trough levels of therapeutic antibodies

Figure 3 Methods to detect trough levels of therapeutic antibodies
Figure 2 Assays for detecting antidrug antibodies to TNF inhibitors

Figure 2 Assays for detecting antidrug antibodies to TNF inhibitors
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 5 Defects in the JAK–STAT signalling pathway

Figure 5 Defects in the JAK–STAT signalling pathway
EULAR OA Trial Bank Study Group Predicting treatment response in subgroups of osteoarthritis patients using individual patient data of worldwide available.

EULAR OA Trial Bank Study Group Predicting treatment response in subgroups of osteoarthritis patients using individual patient data of worldwide available.
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway
Figure 7 Defects in apoptosis

Figure 7 Defects in apoptosis
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 1 Location of HLA variants known to be associated

Figure 1 Location of HLA variants known to be associated
Figure 3 Defects in the T cell receptor signalling pathway

Figure 3 Defects in the T cell receptor signalling pathway

Similar presentations

Ads by Google